认知与衰老项目（CAP）——推进阿尔茨海默病临床前治疗评估
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
作者信息
Reiman Eric M, Langbaum Jessica B, Tariot Pierre N, Lopera Francisco, Bateman Randall J, Morris John C, Sperling Reisa A, Aisen Paul S, Roses Allen D, Welsh-Bohmer Kathleen A, Carrillo Maria C, Weninger Stacie
机构信息
Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
Grupo de Neurosciencias, Universidad de Antioquia, Calle 62 #52-59, Medellin, Colombia.
出版信息
Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.
Abstract
If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.
摘要
如果我们要找到能够延缓、降低风险或完全预防阿尔茨海默病（AD）临床发病的治疗方法，我们就需要更快的方法来评估有前景的临床前AD治疗方案，需要新的合作方式以支持共同目标，还需要有决心加快临床前AD试验的启动和实施。在本文中，我们指出了临床前AD治疗当前面临的一些挑战、机遇和新兴策略。我们介绍了阿尔茨海默病预防协作组织（CAP）——一项召集各方、协调一致并建立共识的倡议，旨在帮助利益相关者严谨、审慎且高效地推进AD预防研究——并且我们展示了CAP对新的临床前AD试验的目标和设计所产生的影响。
相似文献
1
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.认知与衰老项目（CAP）——推进阿尔茨海默病临床前治疗评估
Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.
2
Clinical trials in predementia stages of Alzheimer disease.阿尔茨海默病痴呆前阶段的临床试验。
Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.
3
Subjective Cognitive Decline in Preclinical Alzheimer's Disease.临床前阿尔茨海默病患者的主观认知下降。
Annu Rev Clin Psychol. 2017 May 8;13:369-396. doi: 10.1146/annurev-clinpsy-032816-045136.
4
5
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.疑似前驱性阿尔茨海默病的多奈哌齐治疗受试者区域皮质厚度变化率降低
J Clin Psychiatry. 2016 Dec;77(12):e1631-e1638. doi: 10.4088/JCP.15m10413.
6
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.设计阿尔茨海默病药物临床试验：从 III 期抗体试验结果发布中得到的经验教训：来自欧盟/美国/CTAD 工作组的报告。
Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.
7
Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.唐氏综合征患者临床前和前驱期阿尔茨海默病的认知标志物。
Alzheimers Dement. 2019 Feb;15(2):245-257. doi: 10.1016/j.jalz.2018.08.009. Epub 2018 Nov 28.
8
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.利用磁共振成像在临床前和早期阿尔茨海默病中对脑病理微观结构关联进行体内检测。
Neuroimage. 2017 Mar 1;148:296-304. doi: 10.1016/j.neuroimage.2016.12.026. Epub 2016 Dec 15.
9
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.一项关于疑似前驱期阿尔茨海默病的临床试验中认知衰退和治疗反应的预测因素
Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.
10
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.临床前阿尔茨海默病的轻微认知衰退与生物标志物分期
J Alzheimers Dis. 2015;47(1):231-42. doi: 10.3233/JAD-150128.
引用本文的文献
1
Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease.阿尔茨海默病随机临床试验中的静息态功能磁共振成像
Neuroimage Rep. 2021 Sep 24;1(4):100055. doi: 10.1016/j.ynirp.2021.100055. eCollection 2021 Dec.
2
15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.糖尿病预防试验（DIAN）中15年的纵向基因、临床、认知、影像学和生化测量
medRxiv. 2024 Aug 9:2024.08.08.24311689. doi: 10.1101/2024.08.08.24311689.
3
Plasma β-microglobulin and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: the CABLE study.血浆β-微球蛋白和阿尔茨海默病病理学的脑脊液生物标志物在认知正常的老年人中的研究：CABLE 研究。
Alzheimers Res Ther. 2023 Apr 1;15(1):69. doi: 10.1186/s13195-023-01217-6.
4
Preclinical Alzheimer's dementia: a useful concept or another dead end?临床前阿尔茨海默病性痴呆：一个有用的概念还是另一个死胡同？
Eur J Ageing. 2022 Oct 19;19(4):997-1004. doi: 10.1007/s10433-022-00735-w. eCollection 2022 Dec.
5
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.阿尔茨海默病预防倡议常染色体显性阿尔茨海默病试验的基线数据公共资源。
Alzheimers Dement. 2023 May;19(5):1938-1946. doi: 10.1002/alz.12843. Epub 2022 Nov 14.
6
Planning for Prevention of Parkinson Disease: Now Is the Time.预防帕金森病的规划：现在是时候了。
Neurology. 2022 Aug 16;99(7 Suppl 1):1-9. doi: 10.1212/WNL.0000000000200789.
7
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study.脑脊液神经丝轻链可预测认知健康个体的痴呆发病风险及轻度认知障碍个体的认知衰退速度：一项前瞻性纵向研究
Biomedicines. 2022 Apr 30;10(5):1045. doi: 10.3390/biomedicines10051045.
8
ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.ASIC-E4：晚发性阿尔茨海默病三级遗传风险认知正常志愿者中β-淀粉样蛋白、突触密度与神经炎症的相互作用——研究方案与基线特征
Front Neurol. 2022 Feb 9;13:826423. doi: 10.3389/fneur.2022.826423. eCollection 2022.
9
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.测试淀粉样蛋白级联假说：常染色体显性阿尔茨海默病的预防试验。
Alzheimers Dement. 2022 Dec;18(12):2687-2698. doi: 10.1002/alz.12624. Epub 2022 Feb 24.
10
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.阿尔茨海默病临床谱系中淀粉样蛋白异常的患病率估计
JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216.
本文引用的文献
1
Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.亚利桑那州阿尔茨海默病登记处：全州范围研究招募登记处的策略与成果
J Prev Alzheimers Dis. 2014 Sep;1(2):74-79. doi: 10.14283/jpad.2014.1.
2
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.一项针对高危老年人的饮食、运动、认知训练和血管风险监测的 2 年多领域干预措施，以预防认知能力下降（FINGER）：一项随机对照试验。
Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
3
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.早老素1 E280A常染色体显性阿尔茨海默病家系中生物标志物与年龄的关联：一项横断面研究。
JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.
4
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.临床前阿尔茨海默病认知综合评分：测量与淀粉样蛋白相关的衰退。
JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.
5
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.阿尔茨海默病预防计划综合认知测试分数：早老素1 E280A突变携带者中用于评估临床前阿尔茨海默病治疗的样本量估计
J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927.
6
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.一种基于经验得出的综合认知测试分数，具有更强的能力来跟踪和评估临床前阿尔茨海默病的治疗。
Alzheimers Dement. 2014 Nov;10(6):666-74. doi: 10.1016/j.jalz.2014.02.002. Epub 2014 Apr 21.
7
The A4 study: stopping AD before symptoms begin?A4研究：在症状出现前阻止阿尔茨海默病？
Sci Transl Med. 2014 Mar 19;6(228):228fs13. doi: 10.1126/scitranslmed.3007941.
8
New applications of disease genetics and pharmacogenetics to drug development.疾病遗传学和药物遗传学在药物研发中的新应用。
Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3.
9
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.2 型糖尿病患者强化降压降脂治疗后认知功能和脑结构的变化：一项随机临床试验。
JAMA Intern Med. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656.
10
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.用于轻中度阿尔茨海默病的 solanezumab 的 3 期临床试验。
N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.
Zotero 插件